Blockade of the renin–angiotensin–aldosterone system (RAAS) slows the progression of many forms of kidney disease, but whether this therapy is beneficial in kidney transplant recipients is unclear. A new randomized controlled trial suggests that RAAS blockade is not beneficial in the transplant setting, but the underpowered nature of this study limits its conclusions.
This is a preview of subscription content, log in via an institution to check access.
References
Gondos, A., Dohler, B., Brenner, H. & Opelz, G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation 95, 267–274 (2013).
Knoll, G. A. et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. http://dx.doi.org/10.1016/S2213-8587(15)00368-X (2015).
Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456–1462 (1993).
Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).
Heinze, G. et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J. Am. Soc. Nephrol. 17, 889–899 (2006).
Ibrahim, H. N. et al. Angiotensin II blockade in kidney transplant recipients. J. Am. Soc. Nephrol. 24, 320–327 (2013).
Philipp, T. et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol. Dial. Transplant. 25, 967–976 (2010).
Mariat, C. Early use of renin−angiotensin−aldosterone system inhibitors after renal transplantation. Nat. Clin. Pract. Nephrol. 4, 306–307 (2008).
Rossi, A. P. & Vella, J. P. Hypertension, living kidney donors, and transplantation: where are we today? Adv. Chronic Kidney Dis. 22, 154–164 (2015).
Prokai, A. et al. Calcineurin-inhibition results in upregulation of local renin and subsequent vascular endothelial growth factor production in renal collecting ducts. Transplantation http://dx.doi.org/10.1097/TP.0000000000000961 (2015).
Acknowledgements
R.D.T. is supported by the National Center for Advancing Translational Sciences of the NIH under award number UL1TR001105. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.D.T has received honoraria for consulting and advisory board activities from Amgen, Boehringer–Ingelheim, Celgene, Relypsa, and ZS Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Toto, R. The role of RAAS blockade in kidney transplantation. Nat Rev Nephrol 12, 129–131 (2016). https://doi.org/10.1038/nrneph.2015.201
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2015.201
- Springer Nature Limited
This article is cited by
-
Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation
Scientific Reports (2019)
-
Renin-angiotensin system inhibitors in kidney transplantation: a benefit-risk assessment
Journal of Nephrology (2017)